Nieuws en video's - ORGANOVO HOLDINGS INC. - Pagina 2

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

SAN DIEGO, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced that Chairman and Chief Executive Officer Keith Murphy is scheduled to speak at the 28 th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 29 th at 4:00 p.m. Eastern Time (ET). The presentation will be simultaneously audio...

SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today reported financial results for the fiscal second quarter of 2017 and affirmed its full-year fiscal 2017 and long-range outlook. Net loss was $9.4 million, or $0.10 per share, for the fiscal second quarter of 2017, as compared to $11.3 million, or $0.12 per...

SAN DIEGO, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced that it has received a strong customer response for its second tissue service, the ExVive TM Human Kidney Tissue. This kidney proximal tubule model was launched in September, and is a natural expansion of the Company’s preclinical product and...

SAN DIEGO, Oct. 24, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, will host a conference call on Thursday, November 3, 2016 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fiscal second-quarter 2017 financial results. In advance of the call on November 3, 2016, Organovo will issue its fiscal second-quarter 2017 earnings...

SAN DIEGO, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced the sale of 9,000,000 shares of its common stock in an underwritten public offering at a price to the public of $2.75 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 1,350,000 additional shares of its...

SAN DIEGO, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced that it has commenced an underwritten public offering of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to the completion, size and terms of the offering. Jefferies LLC and Evercore ISI are...

SAN DIEGO, Oct. 11, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today reported preliminary unaudited revenue and net cash utilization results for the fiscal second quarter of 2017 and updated its full-year fiscal 2017 outlook. The Company expects to release full fiscal second-quarter financial results on November 3, 2016....

SAN DIEGO, Oct. 05, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced its plan to develop 3D bioprinted human liver tissue for direct transplantation to patients. The Company is announcing its program to develop this therapeutic tissue based on the achievement of strong results in preclinical studies in animal models...